Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
Our Research Productivity
Departments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Our laboratories cover the full breadth of cancer research. They’re led by some of the leading scientists and physicians in the world.
Scientists from different disciplines come together to focus on a common area in our research institutes.
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program™ was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.Learn more about the Moon Shots Program
Breast cancer treatment
Helper T cells
Head and neck cancers
The p53 expert
Guillermina Lozano, Ph.D., has a long history of making discoveries in the field of cancer genetics. In 1987, she became the first to establish p53 as a transcriptional activator of other genes. Sometimes called the "guardian of the genome," p53 is a tumor supressor gene that, when neutralized, plays a critical role in the development of many types of tumors. In 2017, she became the sixth MD Anderson scientist to be elected to the National Academy of Sciences. This is especially noteworthy since she's the first faculty member that's been chosen based on research conducted while at MD Anderson.
We're designing colorectal cancer vaccines specific for each patient